BioTime and CIRM Join in hESC Deal
The California stem cell agency has reached an agreement with BioTime of Alameda, Ca., to make five clinical grade hESC cell lines available to California-based researchers, it was announced this morning.
In a news release, Michael West, president of the publicly traded BioTime, said,
“We believe this agreement is in the best interests of both the people…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.